Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
Stanford University
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
City of Hope Medical Center
Kyowa Kirin Co., Ltd.
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
miRagen Therapeutics, Inc.
Yale University
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Fox Chase Cancer Center
Columbia University
Therapeutic Advances in Childhood Leukemia Consortium
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Washington
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
Celgene
Stanford University
The Methodist Hospital Research Institute
University of Washington
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Angimmune LLC
Peter MacCallum Cancer Centre, Australia
University of Rochester
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
European Organisation for Research and Treatment of Cancer - EORTC
M.D. Anderson Cancer Center
National Cancer Institute (NCI)